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ABSTRACT   
Major depression is a highly prevalent, multidimensional disorder. Although several classes of 
antidepressants (ADs) are currently available, treatment efficacy is limited and relapse rates are 
high; thus, there is a need to find better therapeutic strategies. Neuroplastic changes in brain 
regions such as the hippocampal dentate gyrus (DG) accompany depression and its amelioration 
with ADs. In this study, the unpredictable chronic mild stress (uCMS) rat model of depression 
was used to determine the molecular mediators of chronic stress and the targets of four ADs 
with different pharmacological profiles (fluoxetine, imipramine, tianeptine and agomelatine) in 
the hippocampal DG. All ADs, except agomelatine, reversed the depression-like behavior and 
neuroplastic changes produced by uCMS. Chronic stress induced significant molecular changes 
that were generally reversed by fluoxetine, imipramine and tianeptine. Fluoxetine primarily 
acted on neurons to reduce the expression of pro-inflammatory response genes and increased a 
set of genes involved in cell metabolism. Similarities were found between the molecular actions 
and targets of imipramine and tianeptine which activated pathways related to cellular protection. 
Agomelatine presented a unique profile, with pronounced effects on genes related to Rho-
GTPase-related pathways in oligodendrocytes and neurons. These differential molecular 
signatures of ADs studied contribute to our understanding of the processes implicated in the 
onset and treatment of depression-like symptoms.  
 
INTRODUCTION  
Major depression is one of the most prevalent neuropsychiatric disorders and is characterized by 
a multifaceted profile of behavioral deficits such as depressed mood, anxiety and cognitive 
impairments (Bessa et al, 2009b; Villanueva, 2013). Strikingly, a high percentage of patients 
treated with the currently available therapies do not show full remission (Lang and Borgwardt, 
2013) and present treatment-resistance (Blier and Blondeau, 2011). Although the 
pathophysiology of depression is still incompletely understood, dysregulation of 
monoaminergic systems, neuroplasticity and immunological responses (Villanueva, 2013; 
Willner et al, 2013) are considered to contribute to the disease. In addition, alterations in 
dendritic plasticity and cytogenesis in the hippocampal dentate gyrus (DG) are observed in the 
brains of animal models of depression and depressed patients (Lucassen et al, 2014; Pittenger 
and Duman, 2008). Importantly, these changes have been implicated in the onset of depressive-
like symptoms and in the actions of ADs in animal models of depression (Bessa et al, 2009a; 
Mateus-Pinheiro et al, 2013a; Mateus-Pinheiro et al, 2013b; Surget et al, 2011).  
ADs are generally classified according to their primary pharmacological targets. The first 
developed ADs were Monoamine Oxidase Inhibitors (MAOi), Tricyclic (TCA) and Tetracyclic 
agents (Li et al, 2012). Second generation ADs include the Selective Serotonin Reuptake 
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Inhibitors (SSRIs), still the most prescribed ADs worldwide, and Norepinephrine and Serotonin 
Reuptake Inhibitors (NSRIs). Atypical ADs include tianeptine whose mechanisms of action are 
poorly understood but which exert potent neuroplastic effects (McEwen et al, 2010), and 
agomelatine, an agonist of melatonin receptors (MT1 and MT2) and an antagonist of the 5HT2c 
receptor that was recently introduced as an AD (Tardito et al, 2012). Despite their diverse 
pharmacological profiles, all of these drugs result in similar behavioral outcomes, suggesting 
overlapping mechanisms of action. Insights into their potentially common molecular targets and 
divergent mechanisms may help develop new treatment strategies that exploit specific 
properties of each individual drug.  
Application of genome-wide analyses of specific brain regions is a potentially valuable 
approach to study drug-specific molecular targets and to generate information that may facilitate 
the development of more efficacious treatments. Such approaches have been previously used to 
investigate the molecular alterations induced by ADs in the hippocampus and other brain 
regions of naïve animals (Conti et al, 2007; Gaska et al, 2012; Korostynski et al, 2013; 
Landgrebe et al, 2002; Lee et al, 2010; Sillaber et al, 2008; Surget et al, 2009; Takahashi et al, 
2006); interpretation of these studies is however limited by the fact that treatment of individuals 
that do not display signs of depressive-like behavior is not comparable to a pathological context 
(Cryan and Slattery, 2007). Previous comparable studies relied on measures of a single 
behavioral index measurement (Drigues et al, 2003; Nakatani et al, 2004), while others using 
multidimensional animal models of depression focused on a single class of AD (Andrus et al, 
2012; Datson et al, 2012; Lisowski et al, 2013; Surget et al, 2009) or two monoaminergic ADs 
(Malki et al, 2012). 
Given the complex nature of depression and the heterogeneous pharmacological profiles of 
available ADs, we considered it important to undertake a comprehensive comparison of the 
molecular effects of commonly-used ADs, focusing on the effects elicited in the DG of rats 
exposed to a well-characterized multidimensional animal model of depression, the unpredictable 
Chronic Mild Stress (uCMS) (Bessa et al, 2009b; Hill et al, 2012). Exposure to uCMS results in 
animals with behavioral deficits, and biometric and neuroplastic changes that match many of 
those found in patients with major depression (Bessa et al, 2009b; Bessa et al, 2013; Hill et al, 
2012; Lucassen et al, 2014). Following induction of disease-like symptoms, animals were 
treated with either fluoxetine, imipramine, tianeptine or agomelatine, and transcriptome analysis 
was subsequently performed on their DGs.  
 
 
METHODS  
Animals and treatments 
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Male Wistar rats (200–250 g, 2 month-old; Charles-River Laboratories) were maintained under 
standard laboratory conditions (lights on: 08:00-20:00; 22
o
C, relative humidity of 55%, ad 
libitum access to food and water). Rats (n= 8-12/ group for behavioral analysis, of which 3 for 
microarrays analysis and 5/6 for morphological analysis) were randomly assigned to one of 
eight groups: non-stressed control (CT)+vehicle; stress-exposed (uCMS)+vehicle; and 
uCMS+fluoxetine (FLX)/ imipramine (IMIP)/ tianeptine (TIAN)/ agomelatine (AGOM). A 
validated unpredictable Chronic Mild Stress protocol (uCMS) was applied for 6 weeks, as 
previously described (Bessa et al, 2009b). During the last 2 weeks of the uCMS, animals were 
injected intraperitoneally daily with one of the four antidepressants (ADs): fluoxetine (10 
mg.kg
-1
 in ultra-pure water; Kemprotec, Middlesborough, UK); imipramine (10 mg.kg
-1 
in 0.9% 
saline solution; Sigma-Aldrich, St Louis, MO, USA); tianeptine (10 mg.kg
-1
 in 0.9% saline 
solution; Kemprotec, Middlesborough, UK) and agomelatine (40 mg.kg
-1
 in 0.5% 
hydroxyethylcellulose; Kemprotec, Middlesborough, UK). The doses were chosen based on 
previous studies (Banasr et al, 2006; Bessa et al, 2009a; McEwen et al, 2010). Body weight was 
monitored weekly (Supplementary Figure S1a). All procedures were carried out in accordance 
with EU Directive 2010/63/EU and NIH guidelines on animal care and experimentation. 
 
Behavioral analysis 
Sucrose consumption test (SCT) 
Anhedonia was assessed for all animals by the SCT 4 and 6 weeks into the uCMS protocol 
(Figure 1a). Baseline sucrose preference (SP) was determined immediately before the start of 
the uCMS protocol (3 independent trials). Before each trial, rats were food- and water-deprived 
for 12h. For testing, animals were presented with two pre-weighed bottles, containing water or 
2% (m/v) sucrose solution for 1h. SP was calculated as previously described (Bessa et al, 
2009b). 
 
Sweet Drive Test (SDT) 
The SDT test was used as an additional measure of anhedonic behavior for all animals, as 
previously described (Mateus-Pinheiro et al, 2014). Briefly, each animal was allowed to explore 
the SDT box for 10 min where sweet (Cheerios®, Nestlé) or regular pellets (Mucedola 4RF21-
GLP) were available. After each trial, preference for sweet pellets was calculated as follows: 
Preference for sweet pellets (%) = Sweet pellets consumed (g) / Total pellets consumed (g) x 
100. Three SDT trials were conducted during the last week of the uCMS protocol (1 trial every 
48 h; Figure 1a). The number of entries into each chamber was used as a measure of 
exploratory behavior (Supplementary Figure S1b). 
 
Novelty suppressed feeding (NSF) test 
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Anxiety-like behavior was assessed using the NSF test at the end of the uCMS protocol. Food-
deprived (18 h) animals were placed in an open-field arena for a maximum of 10 min, where a 
single food pellet was positioned in the center, as previously described (Bessa et al, 2009b). 
After reaching the pellet, animals were individually returned to their home cage and were 
allowed to feed for 10 min. The latency to feed in the open-field arena was used as an index of 
anxiety-like behavior, whereas the food consumption in the home cage provided a measure of 
appetite drive (Supplementary Figure S1c). 
 
Forced swim test (FST) 
The FST was performed at the end of the uCMS protocol. Assays were conducted 24 h after a 5 
min pre-test session, by placing the rats in glass cylinders filled with water (23
o 
C; 50 cm deep) 
for 5 min. Trials were video-recorded and an increase in immobility time was considered to be a 
higher degree of depressive-like behavior. 
 
Corticosterone levels measurement 
For all animals, corticosterone levels were measured in blood serum using a [
125
I] 
radioimmunoassay (RIA) kit (MP Biomedicals, Costa Mesa, CA), according to manufacturer’s 
instructions. Blood sampling (tail venipuncture) was performed during the diurnal nadir (N, 
08:00-09:00) and diurnal zenith (Z, 20:00-21:00) in the fourth (start of ADs treatment) and sixth 
(end of ADs treatment) weeks of the uCMS protocol.  
 
Morphological analysis 
Three-dimensional morphometric analysis was performed on Golgi-Cox stained material 
obtained from rats (5-6/group) that had been transcardially perfused with 0.9% saline and 
further processed, as previously described (Bessa et al, 2009a). For each animal, at least 8 
neurons fulfilling previously-described criteria (Pinto et al, 2014) were analyzed in the dorsal 
and ventral hippocampal dentate gyrus (DG). For each selected neuron, dendritic branches were 
reconstructed at 1000x (oil) magnification using a motorized microscope (Axioplan 2; Carl 
Zeiss, LLC, United States) and Neurolucida software (MBF Bioscience, Williston, VT). Three-
dimensional analysis of the reconstructed neurons was performed using NeuroExplorer software 
(MBF Bioscience, Williston, VT). Measurements from individual neurons from each animal 
were averaged. Total dendritic length was compared among experimental groups. Branching of 
the neurons was evaluated using 3D Sholl analysis; for this, the number of dendritic 
intersections with concentric circles positioned at radial intervals of 20 µm was determined. 
 
Statistical analysis of behavioral data and biometric parameters 
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Statistical analysis was performed using SPSS software (SPSS, Chicago, IL, USA). The 
underlying assumptions of all statistical procedures were assessed. The normal distribution was 
tested using the Kolmogorov-Smirnov test.  Student t-test was used to assess differences 
between Control and uCMS groups and one-Way ANOVA followed by Bonferroni post-hoc 
test was performed to determine differences between ADs-treated groups and uCMS-exposed 
untreated group. Repeated-measures ANOVA was used to assess differences in the body weight 
changes and in the Sholl analysis of the 3D morphometric analysis. Homogeneity of variances 
was assessed with Levene’s test when different groups were compared and, with Mauchly's Test 
of Sphericity when repeated measures were compared. Data transformations were tested when 
the described assumptions were violated. As these transformations did not prove to be useful to 
accomplish normality or homogeneity of variances, the alternative non-parametric tests were 
applied (Mann-Whitney, Kruskal-Wallis and Friedman tests). As all the significant results 
remained the same, the results for the parametric statistical tests were presented. Test statistics 
and p-values are shown for each test. Significance was set at p < 0.05. Effect size, Cohen’s d for 
t-test (d) and eta-squared for ANOVA (η2), is presented whenever statistical significance is 
reached. 
  
Transcriptome analysis 
DG macrodissection  
Whole DG was collected 24 h after the last stressor/AD injection (n= 3 biological 
replicates/group; these animals did not perform NSF and FST tests; Figure 1a). Animals were 
first anesthetized with pentobarbital and transcardially perfused with 0.9% saline. Immediately 
after dissection tissues were frozen and stored at -80
o
 C until further analysis. 
To avoid experimenter-dependent bias, brains were macrodissected by a single investigator. 
Moreover, to confirm the accuracy of the macrodissections, total RNA was isolated from both 
the DG and the remainder hippocampus of CT animals, and gene expression analysis of genes 
predominantly expressed in the DG (Prox1, Dsp and NeuroD1; Supplementary Table 1) 
comparing to the remainder hippocampus was performed by qRT-PCR. 
 
RNA isolation 
Total RNA was isolated from the macrodissected DGs using the miRNeasy Mini kit (Qiagen, 
Germantown, MD, USA), according to the manufacturer’s instructions. The Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) was used to assess RNA quality. 
Only high quality RNA (RIN>7) was used for microarray analysis.  
 
Transcriptome analysis 
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Total RNA (200 ng) was amplified using the Ambion WT Expression Kit and the WT Terminal 
Labeling Kit (Affymetrix, Santa Clara, CA, USA). 2.75µg of amplified cDNA was hybridized 
on Affymetrix Rat Gene 1.0 ST arrays containing about 28,000 probe sets. Staining (Fluidics 
script FS450_0007) and scanning was done according to the Affymetrix expression protocol.  
Expression console (v.1.2, Affymetrix) was used for quality control and to obtain annotated 
normalized RMA gene-level data (standard settings including median polish and sketch-quantile 
normalisation). Statistical analyses were performed by utilizing the statistical programming 
environment R (R_Development_Core_Team, 2013) implemented in CARMAweb (Rainer et 
al, 2006). Genewise testing for differential expression was done employing the limma t-test and 
Benjamini-Hochberg multiple testing correction (FDR < 10%). Regulated gene sets were 
defined by p < 0.01 (limma t-test), fold-change >1.2x, and an average expression >100 in at 
least one group in each pairwise comparison. Heatmaps were generated with CARMAweb. 
Canonical pathway and Function & Disease enrichment analyses were done using the Ingenuity 
pathway (IPA, Qiagen, Redwood City, CA, USA) software. Array data is publically accessible 
from NCBI/GEO (GSE56028). 
Cell type enrichment and mRNA half-life were assessed using previously published datasets 
(Cahoy et al, 2008; Sharova et al, 2009) and analyzed using the online resource Genes2mind 
(www.genes2mind.org) (Korostynski et al, 2013). Enrichment was calculated as fold difference 
between the level of gene expression in a particular cell type and median value of gene 
expression in all three cell types. Mean enrichment of gene expression was calculated as mean 
value of enrichment for each set of drug-regulated genes (Cahoy et al, 2008). 
 
cDNA synthesis and real-time PCR analysis  
Total RNA (500 ng) from the samples used for microarray analysis (DG) and from those used 
for determination of the macrodissections’ accuracy (remainder hippocampus) was reverse-
transcribed using qScript™ cDNA SuperMix (Quanta Biosciences™, Gaithersburg, MD, USA); 
for microRNAs analysis we used the qScript™ microRNA cDNA Synthesis Kit (qScript™ 
microRNA Quantification System, Quanta Biosciences™, Gaithersburg, MD, USA). 
For real time RT-PCR, oligonucleotide primers for selected genes of interest for microarrays 
confirmation and macrodissections’ accuracy determination were designed (NCBI Primer-
BLAST software) (Supplementary Table 1). Reactions were performed in an Applied 
Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems, LLC, CA, USA) using 5x 
HOT FIREPol® EvaGreen® qPCR Mix Plus, ROX (Solis Biodyne, Tartu, Estonia) or 
PerfeCTa® SYBR® Green SuperMix, Low ROX™ (Quanta Biosciences™, Gaithersburg, MD, 
USA), for microRNA confirmation analysis. Target gene expression levels were normalized 
against the housekeeping gene Beta-2-Microglobulin (B2M) or RNA-U6 small nuclear 2 
(RNU6), for microRNA expression analysis. The relative expression was calculated using the 
©    2014 Macmillan Publishers Limited. All rights reserved.
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ΔΔCt method. Results are presented as fold-change of mRNA levels between the respective 
experimental groups after normalization to B2M or RNU6 levels. 
 
RESULTS  
Multi-dimensional behavioral profile 
In order to assess the common beneficial effects of four ADs belonging to different classes – 
fluoxetine, imipramine, tianeptine and agomelatine, we used a well-established animal model of 
depression, the uCMS protocol (Figure 1a). uCMS induced anhedonia, as demonstrated by the 
reduced preference for a sucrose solution in the Sucrose Consumption Test (SCT), both after 
four (t22=1.768, p=0.045, d=0.12) and six weeks of uCMS exposure (t22=3.182, p=0.0043, 
d=0.3152; Figure 1b). The four ADs reversed the uCMS-induced deficits in the SCT 
(F(4,50)=6.468, p=0.0003, η2=0.3410; Figure 1b). Also in the Sweet Drive Test (SDT), reduced 
preference for sweet pellets was observed throughout a three-trial testing paradigm, comparing 
to control (CT) animals (t19=4.887, p=0.0001, d=0.1884; Figure 1c). All ADs except 
agomelatine, reversed the uCMS anhedonic effects (F(4,43)=5.134, p=0.0018, η2=0.3232; Figure 
1c and Supplementary Figure S1b). uCMS induced also increased immobility in the Forced 
Swim test (FST; t18=3.109, p=0.006, d=0.3493; Figure 1d) a measure of behavioral despair, 
which is another hallmark symptom of depressive-like behavior. Again, all ADs except 
agomelatine reversed this phenotype (F(4,39)=6.197, p=0.0006, η2=0.3886; Figure 1d).  
Anxious-like behavior was assessed in the Novelty Suppressed Feeding (NSF) test (Figure 1e 
and Supplementary Figure S1c). As expected, uCMS-exposed animals presented higher 
latency to feed in the NSF compared to CT (t22=4.303, p=0.0003, d=0.4570; Figure 1e) 
indicating increased anxiety-like phenotype. All ADs except agomelatine, reversed this 
phenotype (F(4,55)=7.335, p<0.0001, η2=0.3479; Figure 1e).  
As an additional measure of face and predictive validity, corticosterone levels were measured in 
the serum (Supplementary Figure S2). Disruption of the diurnal pattern of corticosterone 
production in uCMS-exposed animals and reversion by ADs was observed (Supplementary 
Figure S2).  
 
Neuroplastic changes in the hippocampal dentate gyrus (DG)  
Neuroplastic changes were assessed in the dorsal (dDG) and ventral (vDG) hippocampal DG. 
As previously described (Bessa et al, 2009a; Pinto et al, 2014), uCMS-exposed animals 
presented significantly shorter granule neurons in the dDG comparing to CT animals (t8=4.560, 
p=0.0019, d=0.7221; Figure 2a). All ADs, excluding agomelatine, reversed this structural 
change up to the levels of CT (F(4,21)=5.344, p=0.0040, η2=0.5054; Figure 2a). Sholl analysis 
revealed less complex granule neurons in uCMS-exposed compared to CT, and a reversion by 
tianeptine and imipramine (Supplementary Figure S3a).  
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Concerning the vDG, no statistically significant differences were observed in the dendritic 
length between experimental groups (CT vs uCMS: t11=0.7387, p=0.4756; uCMS_ADs vs 
uCMS: F(4,21)=1.910, p=0.1463; Figure 2b). Interestingly, however, the Sholl analysis, disclosed 
significantly more complex neurons in the uCMS animals compared to fluoxetine and 
agomelatine-treated animals (Supplementary Figure S3b). 
 
Microarrays analysis of the DG of uCMS-exposed and AD-treated rats 
To unravel the molecular regulation in the hippocampal DG after uCMS exposure and treatment 
with each of the four ADs, microarrays analysis of macrodissected DG was performed. To 
confirm the specificity of the macrodissections, gene expression analysis was performed in the 
DG of CT animals and compared to the remainder tissue of the hippocampus. The accuracy of 
the dissections was validated by an enrichment of genes predominantly expressed in the DG 
(Neurogenic differentiation 1, NeuroD1, Desmoplakin, Dsp and Prospero homeobox 1, Prox1) 
comparing to the remaining hippocampus (Supplementary Figure S4). A heatmap and a 
cluster dendrogram were generated according to the expression profile of 1311 significantly 
regulated (p<0.01) probe sets (Figure 2c). Mild gene expression changes were observed, with 
most transcripts presenting fold changes between 1.2 and 1.5 (Figure 2d). This genome-wide 
analysis revealed both up- and down-regulation of a large number of molecules, mainly in AD-
treated animals (Figure 3a). The ratio between up- and down-regulated genes was positive for 
all ADs, except agomelatine (FLX: 2.2; IMIP: 1.8; TIAN: 5; AGOM: 0.89).  
 
Transcriptional regulation induced by uCMS-exposure and ADs treatment 
A total of 93 transcripts were altered in uCMS, when compared to CTs (Figure 3a). The top 10 
regulated functional terms associated with these probe sets were identified (Figure 3b). 
Functions related to the categories Cancer, Inflammatory Disease and Metabolic Disease, 
showed the highest number of altered transcripts.  
Regarding the effects of ADs administration, a total of 209 transcripts in fluoxetine-treated, 293 
in tianeptine-treated, 233 in imipramine-treated and 815 in agomelatine-treated were regulated 
comparing to uCMS animals (Figure 3a, 3c and Supplementary Table 2). Despite the higher 
number of regulated transcripts in agomelatine-treated animals, fluoxetine, imipramine and 
tianeptine reversed more uCMS-induced changes, thus normalizing the levels of these 
molecules to the levels of CT (25%, 22%, 32% of reversion, respectively, compared to 12% in 
agomelatine-treated; Table 1 and Supplementary Table 3). Of notice, the list of genes whose 
expression was reversed after ADs treatment, included several microRNAs (e.g. miR-409, miR-
411), Dual specificity protein phosphatase 1 (Dusp1) and Metallothionein 4 (Mt4) (Table 1).  
 
ADs commonly regulated genes 
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Independently of the AD treatment, 11 transcripts were commonly regulated (Figure 3c). The 
majority of them are novel transcripts or coding for uncharacterized predicted proteins 
(Supplementary Table 4). As most of the behavioral effects were observed after treatment with 
fluoxetine, imipramine or tianeptine, and because these three ADs could reverse more 
transcriptional alterations induced by uCMS, we decided to further explore their common 
effects. The analysis of commonly regulated genes revealed 33 probe sets including several 
small nucleolar RNAs (SnoRNA) and microRNAs (e.g. miR-409, miR-411, miR-412), tissue 
plasminogen activator (Plat), Mt4 and Dusp1 (Supplementary Table 4 and 5). A predicted 
network where these genes interact to induce the cellular and behavioral beneficial effects 
observed is depicted in Supplementary Figure S5. The IPA software functions associated to 
this network are related to tissue morphology and connective tissue development and function. 
To confirm the differential expression of genes identified by microarrays analysis, real time RT-
PCR of selected genes for each relevant comparison was performed (Figure 3d-h). These genes 
were chosen based on their neuroplasticity-related function; those without neuroplasticity-
related function were randomly selected from the list of significantly altered genes to avoid bias 
in the microarrays confirmation. Moreover, genes with annotated function which expression 
was reversed by at least three of the ADs were analyzed (Supplementary Table 1).  For all 
selected genes, the differential expression observed by Affymetrix arrays (Figure 3d-h) was 
confirmed. Moreover, a strong correlation between the microarrays and the qRT-PCR fold 
changes was found (correlation coefficient 0.9839, p<0.0001; Figure 3i). 
 
Canonical pathways analysis 
Ingenuity Pathway Analysis (IPA) software was used to identify pathways sensitive to stress 
and to ADs treatment. A list of significantly enriched canonical pathways and the corresponding 
genes is provided for each relevant comparison (Figure 4a-d and Supplementary Table 6). 
Chronic stress exposure induced the up-regulation of only one gene related to the Glutathione 
Redox Reactions pathway. Fluoxetine treatment promoted among others, the down-regulation 
of genes involved in pro-inflammatory response pathways (e.g. IL-6 Signaling, NF-ƙ Ɓ 
Signaling, Acute Phase Response Signaling; Figure 4a), and the up-regulation of genes from 
metabolic pathways (e.g. Pentose Phosphate Pathway and PPAR Signaling; Figure 4a). 
Imipramine treatment induced the down-regulation of several genes involved in drug 
metabolism pathways and the up-regulation of DNA-damage and oxidative stress response 
pathways-related genes (e.g. DNA Double-Strand Break repair by Non-Homologous End 
Joining, NRF2-mediated Oxidative Stress Response; Figure 4b). Tianeptine treatment also 
promoted the down-regulation of genes from drug metabolism pathways and the up-regulation 
of biosynthetic and DNA damage response pathways (Figure 4c). Finally, agomelatine 
treatment induced the down-regulation of genes involved in Cdk5 Signaling, Netrin signaling 
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and Synaptic Long Term Depression, and the up-regulation of genes involved in Rho-GTPases-
related pathways (Figure 4d and Supplementary Table 6). 
 
Nervous tissue cell type enrichment and transcript stability analysis 
To understand the cellular impact of each AD we analyzed which cells types were expressing 
the genes significantly altered after uCMS exposure and ADs treatment. For that, publicly 
available data representing cellular enrichment of individual transcripts in neurons, astrocytes or 
oligodendrocytes was used (Cahoy et al, 2008; Korostynski et al, 2013) (Figure 4e and 
Supplementary Figure S6). Fluoxetine treatment was characterized by an enrichment of genes 
expressed in neurons, whereas agomelatine treatment showed an enrichment of genes expressed 
both in oligodendrocytes and neurons, in comparison to astrocytes. Imipramine and tianeptine 
treatments did not reveal enrichment in any particular cell type. Although not reaching statistical 
significance, uCMS exposure showed a trend for enrichment in transcripts from astrocytes and 
neurons compared to oligodendrocytes (Figure 4e and Supplementary Figure S6).  
To further dissect the function of the differentially regulated genes we analyzed their transcript 
stability (Schwanhausser et al, 2011). Genes with low mRNA stability are frequently involved 
in the regulation of intracellular signaling, whereas long-lived transcripts have a role in cell 
metabolism (Korostynski et al, 2013; Schwanhausser et al, 2011). Similar median mRNA half-
life for each of the treatments was found (Figure 4e). Moreover, these values were close to the 
whole genome median mRNA half-life (7.1h). 
 
 
DISCUSSION 
Although most ADs produce similar behavioral and neuroplastic effects, each AD has a 
characteristic pharmacological and molecular signature, the full exploitation of which could be 
helpful in designing treatments that capture the various pathological facets presented by 
individual depressed patients. To this end, we here sought to identify common and divergent 
molecular targets and pathways of four distinct classes of ADs, represented by fluoxetine, 
imipramine, tianeptine and agomelatine. Our genome-wide analysis focused on the hippocampal 
DG - one of the most studied neural targets of stress and ADs (Lucassen et al, 2014; 
Wainwright and Galea, 2013) - from animals displaying behavioral and endocrine impairments 
akin to depression. These behavioral anomalies were reversed after 2 weeks of treatment with 
fluoxetine, imipramine and tianeptine; agomelatine resulted in only partial behavioral recovery 
although it re-synchronized the diurnal pattern of corticosterone secretion. Notably, fluoxetine, 
imipramine and tianeptine, but not agomelatine, also restored dendritic arborization of the dorsal 
dentate granule cells of the hippocampus to pre-stress levels. No differences were disclosed in 
neuronal dendritic length in the vDG. Given the evidence for a heterogeneous structure and 
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function along the septo-temporal axis of the DG (Kheirbek et al, 2013; Tanti and Belzung, 
2013), with the dDG contributing mainly to functions related to learning and memory, whereas 
the vDG is more related to anxiety and emotional regulation (Tanti & Belzung 2013), we would 
expect also an impact on the vDG. Moreover, while previous reports have shown that the effects 
of some AD treatments on adult hippocampal neurogenesis are region specific along the septo-
temporal axis of the hippocampus, the implication of morphological changes in granule neurons 
has not been fully elucidated (Felice et al, 2012; O'Leary et al, 2012); even thought it has been 
shown a contrasting gradient of stress-induced morphological and physiological changes along 
the septo-temporal axis of the hippocampus (Pinto et al, 2014).  
 
Transcriptional changes induced by uCMS and common reversal mechanisms by AD treatment 
Depression is associated with risk for other pathologies, including cancer and cardiometabolic 
disease  (Lang et al, 2013), which themselves are associated with stress. The present analysis of 
uCMS-exposed animals revealed up- and down-regulation of genes related to these disorders. 
Dusp1, a key negative regulator of the MAP kinase signaling pathway (Huang and Tan, 2012), 
previously related to the pathophysiology of depression in humans and animal models of 
depression (Duric et al, 2010) was up-regulated by uCMS exposure. Importantly, MAP kinase 
pathway has been previously implicated in synaptic plasticity (Duric et al, 2010; Sweatt, 2004) 
and may partly explain the altered neuroplasticity observed in the dDG of uCMS-exposed 
animals. Consistent with their behavior- and neuroplastic-improving actions, all ADs except 
agomelatine, reversed uCMS-upregulated Dusp1 expression. Interestingly, at least two other 
studies have shown the involvement of MAP kinase pathway-related genes in the actions of 
monoaminergic ADs (Malki et al, 2012; Surget et al, 2009), further endorsing the role of this 
pathway as a common strategy used by different AD treatments to reverse the depressive-like 
behaviors. We also observed that a significant number of miRNA precursors were up- and 
down-regulated by uCMS and ADs, respectively. Importantly, among the predicted targets of 
these miRNAs are genes of the MAP kinase pathway (e.g. Map2k1; Map3k1), Calcium-
signaling-related genes (e.g. Calml4, Camkk2) and Rho-signaling-related genes (e.g. RhoGef, 
Rnd2) (Lewis et al, 2005). This finding is interesting in light of the role of miRNAs in neuronal 
development and neuroplasticity (McClung and Nestler, 2008) and their potential for serving as 
new therapeutic targets (Hansen and Obrietan, 2013). Indeed, several recent studies have 
demonstrated that miRNAs are both targets for disruption in mental illness (Kohen et al, 2014) 
but also for AD treatment action (Baudry et al, 2010; O'Connor et al, 2013).  
Noticeably, and given the role of the hippocampal DG cell genesis changes in the onset of 
depressive-like behavior and in the actions of ADs, only minor contribution of key 
neurogenesis-related genes emerged from the comparisons between experimental groups (e.g. 
Sox11, Hes1). We assume that this under-representation may be due to the small proportion of 
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progenitor cells in the tissue (representative of the SGZ) when compared to the remainder 
mature cells. However, an enrichment of genes related to particular aspects of neurogenesis, 
such as, neuronal migration/axonogenesis (e.g. RhoC, Slit1, Epha6, Rasa1, Mapk3, Cxcl12) and 
neuronal fate determination and plasticity (e.g. Dusp1, Cdc20) was found.  
 
AD-specific transcriptional changes 
The present transcriptome analysis showed that, each class of AD left its own molecular 
signature on the DG, but also that they triggered common regulatory effects on a number of 
gene families and pathways. 
Depressed patients and animal models of depression frequently display a deregulated 
neuroinflammatory response (Shelton et al, 2011; Sukoff Rizzo et al, 2012), resulting in 
increased production of pro-inflammatory cytokines that alter neurotransmitter metabolism and 
neural plasticity (Willner et al, 2013). It was interesting to observe here that fluoxetine reduced 
the expression of IL6-signaling and of TNF signaling-related molecules. These pathways have 
been implicated in the development of depressive-like behaviors (Manosso et al, 2013) and 
were shown to be overrepresented in this and other brain regions in response to chronic stress 
(Datson et al, 2012; Sukoff Rizzo et al, 2012). In addition, fluoxetine treatment in uCMS rats 
activated pathways related to cellular respiration and metabolism, a finding in line with the 
presence of long-lived transcripts (Korostynski et al, 2013; Schwanhausser et al, 2011). Further, 
consistent with the findings of other studies (Encinas et al, 2006; Mateus-Pinheiro et al, 2013b; 
Surget et al, 2011), the actions of fluoxetine were more pronounced in neurons than in 
astrocytes and oligodendrocytes. 
Interestingly, imipramine and tianeptine were found to act similarly; the mechanism of action of 
tianeptine, a drug structurally similar to tricyclic agents, is largely unknown (McEwen et al, 
2010). However, we recently predicted that the transcriptional effects of tianeptine, like those of 
imipramine, may involve the modulation of norepinephrine, serotonin and dopamine systems in 
the striatum of naïve mice (Korostynski et al, 2013). In the present study, imipramine and 
tianeptine co-regulated a large number of genes; notably, those were implicated in pathways 
related to drug metabolism, biosynthesis and DNA damage response; this finding suggests that 
the mechanisms of action of the two drugs may involve neuroprotection against the neurotoxic 
effects of stress. Moreover, since both neuronal and non-neuronal cells were predicted to 
respond to these drugs, it is likely that they exert broad actions that ultimately converge to 
reverse the harmful structural and molecular effects of uCMS. 
In contrast to imipramine, fluoxetine and tianeptine, agomelatine acts on two pharmacological 
substrates: melatonin and 5HT2C receptors. Thus, it was not surprising that its application 
produced a behavioral and molecular therapeutic profile that was distinct from that of the other 
ADs tested. Remarkably, agomelatine produced the highest number of transcriptional changes, 
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but reversed only 12% of the transcriptional changes induced by uCMS. Rho-GTPase-signaling 
related genes were among those showing highest up-regulation by agomelatine. Although this 
signaling pathway is an important regulator of morphological neuroplasticity (Negishi and 
Katoh, 2005), agomelatine was strikingly poor in reversing the maladaptive structural (and 
behavioral) alterations induced by uCMS. In silico analysis predicted that agomelatine acts on 
neurons and oligodendrocytes, matching previous observations that melatonin promotes 
oligodendroglial maturation (Olivier et al, 2009).  
This study identifies new molecular correlates of chronic stress that are subject to differential 
regulation by different classes of ADs, and which may therefore underlie their different 
efficacies in reversing the maladaptive neurostructural and behavioral changes observed in the 
DG of animal models of depression. Interestingly, and according to previous studies (Datson et 
al, 2012), little overlap was found between the ADs-regulated genes and pathways in the 
context of this paradigm of induced depressive-like behavior (uCMS) and those regulated in 
naïve AD-treated animals (Gaska et al, 2012; Landgrebe et al, 2002; Sillaber et al, 2008). This 
further emphasizes the relevance of using animal models of depression to explore the molecular 
mechanisms of depressive-like phenotype reversion in the brain. As a result, the new 
information gained may allow exploitation of the unique properties of each AD in the search for 
the next generation of ADs; to further pursue this aim, molecular profiling of other brain regions 
affected in depression will be necessary. The data reported here may also serve to guide drug 
choice in managing symptoms in individual patients with specific genetic variants. 
 
ACKNOWLEDGEMENTS 
We thank Luís Martins, Miguel Carneiro, Ana Lima and Anke Bettenbrock for excellent 
technical assistance. We would also like to acknowledge Patrício Costa for advice on statistical 
analysis. 
 
FUNDING AND DISCLOSURE  
Patrícia Patrício, António Mateus-Pinheiro, Mónica Morais and Nuno Dinis Alves received 
fellowships from the Portuguese Foundation for Science and Technology (FCT). Michal 
Korostynski and Marcin Piechota were funded by POIG De-Me-Ter 3.1 and NCN 
2011/03/D/NZ3/01686 grants. This study was co-funded by the Life and Health Sciences 
Research Institute (ICVS), and ON.2—O NOVO NORTE—North Portugal Regional 
Operational Programme 2007/2013, of the National Strategic Reference Framework (NSRF) 
2007/2013, through the European Regional Development Fund (ERDF) and by the SwitchBox 
Consortium (Contract FP7-Health-F2-2010-259772 from the European Union). 
None of the authors have any conflicts of interest to declare. 
  
©    2014 Macmillan Publishers Limited. All rights reserved.
16 
 
REFERENCES 
Andrus BM, Blizinsky K, Vedell PT, Dennis K, Shukla PK, Schaffer DJ, et al (2012). Gene 
expression patterns in the hippocampus and amygdala of endogenous depression and chronic 
stress models. Mol Psychiatry 17(1): 49-61. 
 
Banasr M, Soumier A, Hery M, Mocaer E, Daszuta A (2006). Agomelatine, a new 
antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 59(11): 
1087-1096. 
 
Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O (2010). miR-16 targets 
the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 
329(5998): 1537-1541. 
 
Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, Palha JA, et al (2009a). The mood-
improving actions of antidepressants do not depend on neurogenesis but are associated with 
neuronal remodeling. Mol Psychiatry 14(8): 764-773, 739. 
 
Bessa JM, Mesquita AR, Oliveira M, Pego JM, Cerqueira JJ, Palha JA, et al (2009b). A trans-
dimensional approach to the behavioral aspects of depression. Front Behav Neurosci 3: 1. 
 
Bessa JM, Morais M, Marques F, Pinto L, Palha JA, Almeida OF, et al (2013). Stress-induced 
anhedonia is associated with hypertrophy of medium spiny neurons of the nucleus accumbens. 
Transl Psychiatry 3: e266. 
 
Blier P, Blondeau C (2011). Neurobiological bases and clinical aspects of the use of 
aripiprazole in treatment-resistant major depressive disorder. J Affect Disord 128 Suppl 1: S3-
10. 
 
Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, et al (2008). A 
transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for 
understanding brain development and function. J Neurosci 28(1): 264-278. 
 
Conti B, Maier R, Barr AM, Morale MC, Lu X, Sanna PP, et al (2007). Region-specific 
transcriptional changes following the three antidepressant treatments electro convulsive therapy, 
sleep deprivation and fluoxetine. Mol Psychiatry 12(2): 167-189. 
 
Cryan JF, Slattery DA (2007). Animal models of mood disorders: Recent developments. Curr 
Opin Psychiatry 20(1): 1-7. 
 
Datson NA, Speksnijder N, Mayer JL, Steenbergen PJ, Korobko O, Goeman J, et al (2012). The 
transcriptional response to chronic stress and glucocorticoid receptor blockade in the 
hippocampal dentate gyrus. Hippocampus 22(2): 359-371. 
 
Drigues N, Poltyrev T, Bejar C, Weinstock M, Youdim MB (2003). cDNA gene expression 
profile of rat hippocampus after chronic treatment with antidepressant drugs. J Neural Transm 
110(12): 1413-1436. 
 
Duric V, Banasr M, Licznerski P, Schmidt HD, Stockmeier CA, Simen AA, et al (2010). A 
negative regulator of MAP kinase causes depressive behavior. Nat Med 16(11): 1328-1332. 
 
Encinas JM, Vaahtokari A, Enikolopov G (2006). Fluoxetine targets early progenitor cells in the 
adult brain. Proc Natl Acad Sci U S A 103(21): 8233-8238. 
 
©    2014 Macmillan Publishers Limited. All rights reserved.
17 
 
Felice D, O'Leary OF, Pizzo RC, Cryan JF (2012). Blockade of the GABA(B) receptor 
increases neurogenesis in the ventral but not dorsal adult hippocampus: relevance to 
antidepressant action. Neuropharmacology 63(8): 1380-1388. 
 
Gaska M, Kusmider M, Solich J, Faron-Gorecka A, Krawczyk MJ, Kulakowski K, et al (2012). 
Analysis of region-specific changes in gene expression upon treatment with citalopram and 
desipramine reveals temporal dynamics in response to antidepressant drugs at the transcriptome 
level. Psychopharmacology (Berl) 223(3): 281-297. 
 
Hansen KF, Obrietan K (2013). MicroRNA as therapeutic targets for treatment of depression. 
Neuropsychiatr Dis Treat 9: 1011-1021. 
 
Hill MN, Hellemans KG, Verma P, Gorzalka BB, Weinberg J (2012). Neurobiology of chronic 
mild stress: parallels to major depression. Neurosci Biobehav Rev 36(9): 2085-2117. 
 
Huang CY, Tan TH (2012). DUSPs, to MAP kinases and beyond. Cell Biosci 2(1): 24. 
 
Kheirbek MA, Drew LJ, Burghardt NS, Costantini DO, Tannenholz L, Ahmari SE, et al (2013). 
Differential control of learning and anxiety along the dorsoventral axis of the dentate gyrus. 
Neuron 77(5): 955-968. 
 
Kohen R, Dobra A, Tracy JH, Haugen E (2014). Transcriptome profiling of human 
hippocampus dentate gyrus granule cells in mental illness. Transl Psychiatry 4: e366. 
 
Korostynski M, Piechota M, Dzbek J, Mlynarski W, Szklarczyk K, Ziolkowska B, et al (2013). 
Novel drug-regulated transcriptional networks in brain reveal pharmacological properties of 
psychotropic drugs. BMC Genomics 14: 606. 
 
Landgrebe J, Welzl G, Metz T, van Gaalen MM, Ropers H, Wurst W, et al (2002). Molecular 
characterisation of antidepressant effects in the mouse brain using gene expression profiling. J 
Psychiatr Res 36(3): 119-129. 
 
Lang UE, Borgwardt S (2013). Molecular mechanisms of depression: perspectives on new 
treatment strategies. Cell Physiol Biochem 31(6): 761-777. 
 
Lee JH, Ko E, Kim YE, Min JY, Liu J, Kim Y, et al (2010). Gene expression profile analysis of 
genes in rat hippocampus from antidepressant treated rats using DNA microarray. Bmc Neurosci 
11: 152. 
 
Lewis BP, Burge CB, Bartel DP (2005). Conserved seed pairing, often flanked by adenosines, 
indicates that thousands of human genes are microRNA targets. Cell 120(1): 15-20. 
 
Li X, Frye MA, Shelton RC (2012). Review of pharmacological treatment in mood disorders 
and future directions for drug development. Neuropsychopharmacology 37(1): 77-101. 
 
Lisowski P, Juszczak GR, Goscik J, Stankiewicz AM, Wieczorek M, Zwierzchowski L, et al 
(2013). Stress susceptibility-specific phenotype associated with different hippocampal 
transcriptomic responses to chronic tricyclic antidepressant treatment in mice. Bmc Neurosci 14: 
144. 
 
Lucassen PJ, Pruessner J, Sousa N, Almeida OF, Van Dam AM, Rajkowska G, et al (2014). 
Neuropathology of stress. Acta Neuropathol 127(1): 109-135. 
 
©    2014 Macmillan Publishers Limited. All rights reserved.
18 
 
Malki K, Lourdusamy A, Binder E, Paya-Cano J, Sluyter F, Craig I, et al (2012). 
Antidepressant-dependent mRNA changes in mouse associated with hippocampal neurogenesis 
in a mouse model of depression. Pharmacogenet Genomics 22(11): 765-776. 
 
Manosso LM, Neis VB, Moretti M, Daufenbach JF, Freitas AE, Colla AR, et al (2013). 
Antidepressant-like effect of alpha-tocopherol in a mouse model of depressive-like behavior 
induced by TNF-alpha. Prog Neuropsychopharmacol Biol Psychiatry 46: 48-57. 
 
Mateus-Pinheiro A, Patricio P, Alves ND, Machado-Santos AR, Morais M, Bessa JM, et al 
(2014). The Sweet Drive Test: refining phenotypic characterization of anhedonic behavior in 
rodents. Front Behav Neurosci 8: 74. 
 
Mateus-Pinheiro A, Patricio P, Bessa JM, Sousa N, Pinto L (2013a). Cell genesis and dendritic 
plasticity: a neuroplastic pas de deux in the onset and remission from depression. Mol 
Psychiatry 18(7): 748-750. 
 
Mateus-Pinheiro A, Pinto L, Bessa JM, Morais M, Alves ND, Monteiro S, et al (2013b). 
Sustained remission from depressive-like behavior depends on hippocampal neurogenesis. 
Transl Psychiatry 3: e210. 
 
McClung CA, Nestler EJ (2008). Neuroplasticity mediated by altered gene expression. 
Neuropsychopharmacology 33(1): 3-17. 
 
McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, et al (2010). The 
neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic 
modulation. Mol Psychiatry 15(3): 237-249. 
 
Nakatani N, Aburatani H, Nishimura K, Semba J, Yoshikawa T (2004). Comprehensive 
expression analysis of a rat depression model. Pharmacogenomics J 4(2): 114-126. 
 
Negishi M, Katoh H (2005). Rho family GTPases and dendrite plasticity. Neuroscientist 11(3): 
187-191. 
 
O'Connor RM, Grenham S, Dinan TG, Cryan JF (2013). microRNAs as novel antidepressant 
targets: converging effects of ketamine and electroconvulsive shock therapy in the rat 
hippocampus. Int J Neuropsychopharmacol 16(8): 1885-1892. 
 
O'Leary OF, O'Connor RM, Cryan JF (2012). Lithium-induced effects on adult hippocampal 
neurogenesis are topographically segregated along the dorso-ventral axis of stressed mice. 
Neuropharmacology 62(1): 247-255. 
 
Olivier P, Fontaine RH, Loron G, Van Steenwinckel J, Biran V, Massonneau V, et al (2009). 
Melatonin promotes oligodendroglial maturation of injured white matter in neonatal rats. Plos 
One 4(9): e7128. 
 
Pinto V, Costa JC, Morgado P, Mota C, Miranda A, Bravo FV, et al (2014). Differential impact 
of chronic stress along the hippocampal dorsal-ventral axis. Brain Struct Funct; e-pub ahead of 
print 6 February 2014. doi: 10.1007/s00429-014-0713-0 
 
Pittenger C, Duman RS (2008). Stress, depression, and neuroplasticity: a convergence of 
mechanisms. Neuropsychopharmacology 33(1): 88-109. 
 
R_Development_Core_Team (2013).R: A language and environment for statistical computing. 
http://www.R-project.org/ 
 
©    2014 Macmillan Publishers Limited. All rights reserved.
19 
 
Rainer J, Sanchez-Cabo F, Stocker G, Sturn A, Trajanoski Z (2006). CARMAweb: 
comprehensive R- and bioconductor-based web service for microarray data analysis. Nucleic 
Acids Res 34(Web Server issue): W498-503. 
 
Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al (2011). Global 
quantification of mammalian gene expression control. Nature 473(7347): 337-342. 
 
Sharova LV, Sharov AA, Nedorezov T, Piao Y, Shaik N, Ko MS (2009). Database for mRNA 
half-life of 19 977 genes obtained by DNA microarray analysis of pluripotent and 
differentiating mouse embryonic stem cells. DNA Res 16(1): 45-58. 
 
Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA, et al 
(2011). Altered expression of genes involved in inflammation and apoptosis in frontal cortex in 
major depression. Mol Psychiatry 16(7): 751-762. 
 
Sillaber I, Panhuysen M, Henniger MS, Ohl F, Kuhne C, Putz B, et al (2008). Profiling of 
behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI 
paroxetine. Psychopharmacology (Berl) 200(4): 557-572. 
 
Sukoff Rizzo SJ, Neal SJ, Hughes ZA, Beyna M, Rosenzweig-Lipson S, Moss SJ, et al (2012). 
Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like 
phenotypes. Transl Psychiatry 2: e199. 
 
Surget A, Tanti A, Leonardo ED, Laugeray A, Rainer Q, Touma C, et al (2011). 
Antidepressants recruit new neurons to improve stress response regulation. Mol Psychiatry 
16(12): 1177-1188. 
 
Surget A, Wang Y, Leman S, Ibarguen-Vargas Y, Edgar N, Griebel G, et al (2009). 
Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model 
of depression and of antidepressant reversal. Neuropsychopharmacology 34(6): 1363-1380. 
 
Sweatt JD (2004). Mitogen-activated protein kinases in synaptic plasticity and memory. Curr 
Opin Neurobiol 14(3): 311-317. 
 
Takahashi Y, Washiyama K, Kobayashi T, Hayashi S (2006). Gene expression in the brain from 
fluoxetine-injected mouse using DNA microarray. Ann N Y Acad Sci 1074: 42-51. 
 
Tanti A, Belzung C (2013). Neurogenesis along the septo-temporal axis of the hippocampus: are 
depression and the action of antidepressants region-specific? Neuroscience 252: 234-252. 
 
Tardito D, Molteni R, Popoli M, Racagni G (2012). Synergistic mechanisms involved in the 
antidepressant effects of agomelatine. Eur Neuropsychopharmacol 22 Suppl 3: S482-486. 
 
Villanueva R (2013). Neurobiology of major depressive disorder. Neural Plast Volume 2013: 
Article ID 873278. 
 
Wainwright SR, Galea LA (2013). The neural plasticity theory of depression: assessing the roles 
of adult neurogenesis and PSA-NCAM within the hippocampus. Neural Plast Volume 2013: 
Article ID 805497. 
 
Willner P, Scheel-Kruger J, Belzung C (2013). The neurobiology of depression and 
antidepressant action. Neurosci Biobehav Rev 37(10 Pt 1): 2331-2371. 
 
 
 
©    2014 Macmillan Publishers Limited. All rights reserved.
20 
 
Table 1: List of uCMS-induced transcriptional alterations reversed by antidepressants (ADs) treatment. 
Last row shows the percentage of molecules which expression was reversed by each of the ADs.   
Probe set Gene symbol or ID 
Fold Change 
uCMS-
exposed 
FLX-
treated 
IMIP-
treated 
TIAN-
treated 
AGOM-
treated 
10764367 Mir181b-1 1.49 • -1.62 -1.52 • 
10887050 Mir411 1.29 -1.55 -1.61 -1.43 • 
10887104 Mir409 1.29 -1.44 -1.44 -1.44 -1.52 
10816485 Mir9-1 1.29 • -1.27 • • 
10887110 Mir410 1.23 -1.36 • -1.24 • 
10887048 Mir379 1.21 -1.47 -1.34 • • 
10863679 Cml5 1.35 • • -1.41 -1.76 
10732652 Dusp1 1.32 -1.47 -1.53 -1.61 - 
10725778 Nupr1 1.31 • • -1.31 • 
10799977 Enkur 1.23 -1.23 • -1.34 • 
10719648 Zfp61 1.23 • • • -1.28 
10864918 Ret 1.21 • • • -1.31 
10828841 Rab44 -1.22 • • 1.24 • 
10809406 Mt4 -1.23 1.25 1.24 1.25 • 
10712196 Pkp3 -1.24 • • 1.21 • 
10722273 Fancf -1.27 1.22 • 1.22 • 
10747214 Krt31 -1.29 • • 1.28 1.27 
10759553 Lrrc8e -1.40 • 1.29 1.43 1.42 
10731444 Rsl1d1 -1.71 • • • 1.41 
10788070 ENSRNOT00000059482 -1.47 1.59 1.61 1.54 1.48 
10806413 ENSRNOT00000060679 -1.34 • 1.44 1.49 • 
10767075 ENSRNOT00000053847 -1.38 1.52 • 1.48 • 
10722578 ENSRNOT00000055917 -1.38 • 1.39 1.42 • 
10752628 ENSRNOT00000063656 -1.42 1.41 • • • 
10775226 ENSRNOT00000047758 -1.43 1.42 1.50 • • 
10755670 ENSRNOT00000053925 -1.57 • 1.94 2.15 • 
10749818 ENSRNOT00000053950 -1.66 2.04 1.73 1.85 • 
10785624 ENSRNOT00000057823 -1.22 1.23 • • • 
10763318 ENSRNOT00000049616 -1.24 1.28 1.27 • • 
10744141 ENSRNOT00000054292 -1.25 • • 1.24 • 
10780922 ENSRNOT00000032631 -1.25 1.26 • 1.38 1.34 
10857470 ENSRNOT00000056864 -1.26 • 1.25 • • 
10702579 ENSRNOT00000060826 -1.27 1.32 1.30 1.36 • 
10724150 ENSRNOT00000031043 -1.28 • • 1.22 • 
10707740 ENSRNOT00000055911 -1.29 1.30 1.34 1.34 • 
10873723 LOC100360708 1.28 • -1.38 -1.43 • 
10744306 LOC497940 1.24 -1.26 • • • 
10926285 LOC680955 1.21 • • -1.28 • 
10805591 LOC689153 -1.26 1.22 • 1.35 1.44 
10937658 LOC686031 -1.58 1.58 1.48 1.48 1.56 
10783022 RGD1310110 1.25 • • • • 
10726241 RGD1560958 -1.29 1.22 • 1.22 • 
10817543 FQ225205 -1.87 2.10 • • • 
% of reversed alterations - 25 22 33 12 
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FIGURES LEGENDS: 
Figure 1: Multi-dimensional behavioral characterization of the animal model of depression 
used (unpredictable chronic mild stress – uCMS) before and after treatment with four different 
ADs. (a) uCMS protocol was applied to the animals for 6 weeks; 4 different ADs (fluoxetine, 
FLX; imipramine, IMIP; tianeptine, TIAN; agomelatine, AGOM) were administered in the last 
2 weeks of the uCMS protocol. Behavioral profiling was performed using a battery of tests to 
assess mood and anxiety-like behavior (n=8-12). Animals used for microarrays analysis (n=3) 
were sacrificed immediately after the end of uCMS protocol/AD-treatment (Sacrifice 1). 
Animals used for morphological analysis (n=5/6) were sacrificed on week 7, after performing 
all behavioral tests (Sacrifice 2). (b) Sucrose consumption test (SCT) was performed at the 4
th
 
and 6
th
 weeks of the uCMS protocol to evaluate anhedonia. uCMS induced an anhedonic profile 
in untreated rats (SAL), but all ADs reversed this phenotype. (c) Sweet Drive Test (SDT) was 
used as an additional measure of anhedonia. uCMS proved to induce anhedonia as observed in 
Trial 3 (T3; Trial 1(T1) and Trial 2 (T2) - data not shown), that was reversed by FLX, IMIP and 
TIAN, but not AGOM. (d) In the Forced Swim Test (FST) uCMS induced increased immobility 
that was reversed by administration of FLX, IMIP and TIAN, but not AGOM. (e) uCMS 
exposure produced anxious-like behavior, as assessed in the Novelty Suppressed Feeding (NSF) 
test. All ADs, except AGOM reversed this phenotype. Error bars denote SEM. * Denotes the 
effect of uCMS-exposure; # Denotes the effect of ADs comparing to untreated uCMS-exposed 
animals. */# p<0.05; **/## p<0.01; ***/### p<0.001. n=8-12 animals per group. 
 
Figure 2: Neuronal morphology and gene expression analysis of the hippocampal DG. (a) 
Representative pictures of reconstructed Golgi-impregnated granule neurons of the dorsal DG 
and average total dendritic length. Untreated uCMS-exposed animals (SAL) show a decrease in 
the total dendritic length that is recovered by fluoxetine (FLX), imipramine (IMIP) and 
tianeptine (TIAN) administration. (b) Representative pictures of reconstructed Golgi-
impregnated granule neurons of the ventral DG and total dendritic length. No statistically 
significant differences were observed between groups. Error bars denote SEM. * Denotes the 
effect of uCMS-exposure; # Denotes the effect of antidepressants comparing to untreated 
uCMS-exposed animals. */# p<0.05; **/## p<0.01; ***/### p<0.001. n=5 or 6 animals per 
group. (c) Heatmap and cluster dendrogram obtained from the microarrays analysis of all 
samples generated according to the expression profile of 1311 significantly regulated (p<0.01) 
probe sets. (d) Magnitude of the transcriptional response to chronic stress exposure (uCMS) and 
ADs treatment in the DG; the majority of fold changes are between 1.2 and 1.5-fold.  
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Figure 3: Microarrays analysis of the DG of Control, uCMS-exposed and antidepressant-treated 
rats. (a) Number of up- and down-regulated genes in uCMS vs CT animals and in ADs-treated 
vs uCMS animals. (b) Top 10 significantly enriched functional categories identified with 
Ingenuity Pathway Analysis (IPA) Software in uCMS-exposed vs Control animals. Shown are 
the terms with the highest number of genes, as indicated by the bars. (c) Venn diagram 
depicting the number of significantly regulated transcripts (p<0.01, FC>1.2x, average 
expression>100) after 2 weeks of AD treatment, and overlap between treatments. (d-h) 
Confirmation of the microarrays data was performed by qRT-PCR of selected genes, for each 
relevant comparison. White bars depict the linear fold change (FC) of mRNA levels between the 
respective experimental groups after normalization to B2M/RNU6 (microRNAs) mRNA levels; 
Grey bars depict the observed linear FC in the Affymetrix microarrays. Error bars denote SEM. 
*Denotes statistical differences between groups for each relevant comparison after 
normalization to B2M/RNU6 mRNA levels; *p<0.05; n=3 per group. (i) Linear regression 
analysis of FC from microarrays and qRT-PCR of all selected genes for confirmation. 
Correlation coefficient and p-value are indicated in the graph. Abbreviations: CT-control; 
uCMS-unpredictable chronic mild stress; FLX-fluoxetine; IMIP-imipramine; TIAN-tianeptine; 
AGOM-agomelatine. 
 
Figure 4: Characterization of ADs effects and cellular targets. (a-d) Top 10 significantly 
enriched canonical pathways identified with Ingenuity Pathway Analysis (IPA) Software in 
untreated uCMS rats vs FLX-treated (a), IMIP-treated (b), TIAN-treated (c), AGOM-treated (d) 
animals. Pathways presenting the higher number of regulated transcripts were selected. (e) 
Predicted cell type enrichment and median mRNA half-life (mRNA t½) of uCMS- and ADs-
responsive genes. Median mRNA t½ for whole-transcriptome was 7.1h. Error bars denote SEM. 
*p<0.05; ***p<0.001. Abbreviations: CT-control; uCMS-unpredictable chronic mild stress; 
FLX-fluoxetine; IMIP-imipramine; TIAN-tianeptine; AGOM-agomelatine. 
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